Factors Associated with the Non-Exacerbator Phenotype of Chronic Obstructive Pulmonary Disease

References

• Vestbo J. COPD: definition and phenotypes. Clin Chest Med. 2014;35(1):1–6. doi:10.1016/j.ccm.2013.10.010
   PubMed Web of Science ®Google Scholar
• Vestbo J, Edwards LD, Scanlon PD, et al. Changes in forced expiratory volume in 1 second over time in COPD. N Engl J Med. 2011;365(13):1184–1192. doi:10.1056/NEJMoa1105482
   PubMed Web of Science ®Google Scholar
• Agustí A, Edwards LD, Rennard SI, et al. Persistent systemic inflammation is associated with poor clinical outcomes in COPD: a novel phenotype. PLoS One. 2012;7(5):e37483. doi:10.1371/journal.pone.0037483
   PubMed Web of Science ®Google Scholar
• Hurst JR, Vestbo J, Anzueto A, et al. Susceptibility to exacerbation in chronic obstructive pulmonary disease. N Engl J Med. 2010;363(12):1128–1138. doi:10.1056/NEJMoa0909883
   PubMed Web of Science ®Google Scholar
• Rouzic OL, Roche N, Cortot AB, et al. Defining the “frequent exacerbator” phenotype in COPD: a hypothesis-free approach. CHEST. 2018;153(5):1106–1115. doi:10.1016/j.chest.2017.10.009
   PubMedGoogle Scholar
• Celli BR, Fabbri LM, Aaron SD, et al. An updated definition and severity classification of chronic obstructive pulmonary disease exacerbations: the Rome proposal. Am J Respir Crit Care Med. 2021;204(11):1251–1258. doi:10.1164/rccm.202108-1819PP
   PubMed Web of Science ®Google Scholar
• Stöber A, Lutter JI, Schwarzkopf L, et al. Impact of lung function and exacerbations on health-related quality of life in COPD patients within one year: real-world analysis based on claims data. COPD. 2021;16:2637–2651. doi:10.2147/COPD.S313711
   Google Scholar
• Doll H, Miravitlles M. Health-related QOL in acute exacerbations of chronic bronchitis and chronic obstructive pulmonary disease: a review of the literature. PharmacoEconomics. 2005;23(4):345–363. doi:10.2165/00019053-200523040-00005
   PubMed Web of Science ®Google Scholar
• Wedzicha JA, Seemungal TA. COPD exacerbations: defining their cause and prevention. Lancet. 2007;370(9589):786–796. doi:10.1016/S0140-6736(07)61382-8
   PubMed Web of Science ®Google Scholar
• Mantero M, Rogliani P, Di Pasquale M, et al. Acute exacerbations of COPD: risk factors for failure and relapse. COPD. 2017;12:2687–2693. doi:10.2147/COPD.S145253
   Google Scholar
• Lipson DA, Crim C, Criner GJ, et al. Reduction in all-cause mortality with fluticasone furoate/umeclidinium/vilanterol in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2020;201(12):1508–1516. doi:10.1164/rccm.201911-2207OC
   PubMed Web of Science ®Google Scholar
• Rabe KF, Martinez FJ, Ferguson GT, et al. Triple inhaled therapy at two glucocorticoid doses in moderate-to-very-severe COPD. N Engl J Med. 2020;383(1):35–48. doi:10.1056/NEJMoa1916046
   PubMed Web of Science ®Google Scholar
• Calverley PCA, Anderson J, Celli B, et al. Salmeterol and Fluticasone Propionate and Survival in Chronic Obstructive Pulmonary Disease. N Engl J Med. ;356(8):775–789
   PubMedGoogle Scholar
• Janson C, Johansson G, Ställberg B, et al. Identifying the associated risks of pneumonia in COPD patients: arctic an observational study. Respir Res. 2018;19(1):172. doi:10.1186/s12931-018-0868-y
   PubMed Web of Science ®Google Scholar
• Praxis-studien. Astma KOL; 2022. Available from: http://www.praxisstudien.se/. Accessed March 27, 2023.
   Google Scholar
• de Oca MM, Halbert RJ, Lopez MV, et al. The chronic bronchitis phenotype in subjects with and without COPD: the PLATINO study. Eur Respir J. 2012;40(1):28–36. doi:10.1183/09031936.00141611
   PubMed Web of Science ®Google Scholar
• Landbo C, Prescott E, Lange P, Vestbo J, Almdal TP. Prognostic value of nutritional status in chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 1999;160(6):1856–1861. doi:10.1164/ajrccm.160.6.9902115
   PubMed Web of Science ®Google Scholar
• Ferreira IM, Brooks D, White J, Goldstein R Nutritional supplementation for stable chronic obstructive pulmonary disease.Cochrane Database Syst Rev. ;12: CD000998.
   Google Scholar
• Vestbo J, Prescott E, Almdal T, et al. Body Mass, Fat-Free Body Mass, and Prognosis in Patients with Chronic Obstructive Pulmonary Disease from a Random Population Sample - findings from the Copenhagen City Heart Study. Am J Respir Crit Care Med. ;173(1):79–83
   PubMedGoogle Scholar
• Jones PW, Harding G, Berry P, Wiklund I, Chen WH, Kline Leidy N. Development and first validation of the COPD Assessment Test. Eur Respir J. 2009;34(3):648–654. doi:10.1183/09031936.00102509
   PubMed Web of Science ®Google Scholar
• GOLD-REPORT-2021-v1.1-25Nov20_WMV.pdf; 2022. Available from: https://goldcopd.org/wp-content/uploads/2020/11/GOLD-REPORT-2021-v1.1-25Nov20_WMV.pdf. Accessed March 27, 2023.
   Google Scholar
• Cooper BG, Stocks J, Hall GL, et al. The Global Lung Function Initiative (GLI) Network: bringing the world’s respiratory reference values together. Breathe. 2017;13(3):e56–64. doi:10.1183/20734735.012717
   Web of Science ®Google Scholar
• Varol Y, Ozacar R, Balci G, Usta L, Taymaz Z. Assessing the effectiveness of the COPD Assessment Test (CAT) to evaluate COPD severity and exacerbation rates. COPD. 2014;11(2):221–225. doi:10.3109/15412555.2013.836169
   PubMedGoogle Scholar
• Müllerova H, Maselli DJ, Locantore N, et al. Hospitalized Exacerbations of COPD: risk Factors and Outcomes in the ECLIPSE Cohort. Chest. 2015;147(4):999–1007. doi:10.1378/chest.14-0655
   PubMed Web of Science ®Google Scholar
• Donaldson GC. Relationship between exacerbation frequency and lung function decline in chronic obstructive pulmonary disease. Thorax. 2002;57(10):847–852. doi:10.1136/thorax.57.10.847
   PubMed Web of Science ®Google Scholar
• Putcha N, Drummond M, Wise R, Hansel N. Comorbidities and chronic obstructive pulmonary disease: prevalence, influence on outcomes, and management. Semin Respir Crit Care Med. 2015;36(04):575–591. doi:10.1055/s-0035-1556063
   PubMedGoogle Scholar
• Sundh J, Ställberg B, Lisspers K, Montgomery SM, Janson C. Co-morbidity, body mass index and quality of life in COPD using the clinical COPD questionnaire. COPD. 2011;8(3):173–181. doi:10.3109/15412555.2011.560130
   PubMedGoogle Scholar
• Kim V, Criner GJ. Chronic bronchitis and chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2013;187(3):228–237. doi:10.1164/rccm.201210-1843CI
   PubMed Web of Science ®Google Scholar
• Sundh J, Johansson G, Larsson K, et al. The phenotype of concurrent chronic bronchitis and frequent exacerbations in patients with severe COPD attending Swedish secondary care units. COPD;2015. 2327. doi:10.2147/COPD.S91362
   Google Scholar
• Watson L, Vestbo J, Postma DS, et al. Gender differences in the management and experience of chronic obstructive pulmonary disease. Respir Med. 2004;98(12):1207–1213. doi:10.1016/j.rmed.2004.05.004
   PubMed Web of Science ®Google Scholar
• Åberg J, Hasselgren M, Montgomery S, et al. Sex-related differences in management of Swedish patients with a clinical diagnosis of chronic obstructive pulmonary disease. COPD. 2019;14:961–969. doi:10.2147/COPD.S193311
   Google Scholar
• Celli B, Vestbo J, Jenkins CR, et al. Sex differences in mortality and clinical expressions of patients with chronic obstructive pulmonary disease: the TORCH Experience. Am J Respir Crit Care Med. 2011;183(3):317–322. doi:10.1164/rccm.201004-0665OC
   PubMed Web of Science ®Google Scholar
• Lamprecht B, Vanfleteren LE, Studnicka M, et al. Sex-related differences in respiratory symptoms: results from the BOLD Study. Eur Respir J. 2013;42(3):858–860. doi:10.1183/09031936.00047613
   PubMedGoogle Scholar
• Lisspers K, Larsson K, Janson C, et al. Gender differences among Swedish COPD patients: results from the Arctic, a real-world retrospective cohort study. npj Prim Care Respir Med. 2019;29(1):45. doi:10.1038/s41533-019-0157-3
   PubMed Web of Science ®Google Scholar
• Putcha N, Anzueto AR, Calverley PMA, et al. Mortality and exacerbation risk by body mass index in patients with COPD in TIOSPIR and UPLIFT. Ann ATS. 2022;19(2):204–213. doi:10.1513/AnnalsATS.202006-722OC
   Google Scholar
• Lambert AA, Putcha N, Drummond MB, et al. Obesity is associated with increased morbidity in moderate to severe COPD. Chest. 2017;151(1):68–77. doi:10.1016/j.chest.2016.08.1432
   PubMed Web of Science ®Google Scholar
• Axson EL, Bottle A, Cowie MR, Quint JK. Relationship between heart failure and the risk of acute exacerbation of COPD. Thorax. 2021;76(8):807–814. doi:10.1136/thoraxjnl-2020-216390
   PubMed Web of Science ®Google Scholar
• Abusaid GH, Barbagelata A, Tuero E, Mahmood A, Sharma G. Diastolic dysfunction and COPD exacerbation. Postgrad Med. 2009;121(4):76–81. doi:10.3810/pgm.2009.07.2033
   PubMed Web of Science ®Google Scholar
• Barnes PJ, Celli BR. Systemic manifestations and comorbidities of COPD. Eur Respir J. 2009;33(5):1165–1185. doi:10.1183/09031936.00128008
   PubMed Web of Science ®Google Scholar
• de Boer AR, Vaartjes I, Gohar A, et al. Heart failure with preserved, mid-range, and reduced ejection fraction across health care settings: an observational study. ESC Heart Fail. 2022;9(1):363–372. doi:10.1002/ehf2.13742
   PubMedGoogle Scholar
• Lopez-Campos JL, Abad-Arranz M, Calero Acuña C, et al. Determinants for changing the treatment of COPD: a regression analysis from a clinical audit. COPD;2016. 1171. doi:10.2147/COPD.S103614
   Google Scholar